Anti‐factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

Den Uijl, 2009, Clinical outcome of moderate haemophilia compared with severe and mild haemophilia, Haemophilia, 15, 83, 10.1111/j.1365-2516.2008.01837.x Berntorp, 2012, Modern haemophilia care, Lancet, 379, 1447, 10.1016/S0140-6736(11)61139-2 Astermark, 2007, A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study, Blood, 109, 546, 10.1182/blood-2006-04-017988 Hay, 2012, The principal results of the International Immune Tolerance Study: a randomized dose comparison, Blood, 119, 1335, 10.1182/blood-2011-08-369132 Manco‐Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med, 357, 535, 10.1056/NEJMoa067659 Oldenburg, 2011, Prophylaxis in bleeding disorders, Thromb Res, 127, S14, 10.1016/j.thromres.2010.10.005 Ragni, 2012, Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres, Haemophilia, 18, 63, 10.1111/j.1365-2516.2011.02554.x Kitazawa, 2012, A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model, Nat Med, 18, 1570, 10.1038/nm.2942 Sampei, 2013, Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity, PLoS ONE, 8, e57479, 10.1371/journal.pone.0057479 Den Uijl, 2011, Clinical severity of haemophilia A: does the classification of the 1950s still stand?, Haemophilia, 17, 849, 10.1111/j.1365-2516.2011.02539.x Shima, 2008, New assays for monitoring haemophilia treatment, Haemophilia, 14, 83, 10.1111/j.1365-2516.2008.01737.x Srivastava, 2013, Guidelines for the management of hemophilia, Haemophilia, 19, e1, 10.1111/j.1365-2516.2012.02909.x Lillicrap, 2013, The future of hemostasis management, Pediatr Blood Cancer, 60, S44, 10.1002/pbc.24334 Pipe, 2012, The hope and reality of long‐acting hemophilia products, Am J Hematol, 87, S33, 10.1002/ajh.23146 Collins, 2012, Personalized prophylaxis, Haemophilia, 18, 131, 10.1111/j.1365-2516.2012.02838.x Deng, 2011, Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?, MAbs, 3, 61, 10.4161/mabs.3.1.13799 Dong, 2011, Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first‐in‐human prediction, Clin Pharmacokinet, 50, 131, 10.2165/11537430-000000000-00000 Ponce, 2009, Immunogenicity of biologically‐derived therapeutics: assessment and interpretation of nonclinical safety studies, Regul Toxicol Pharmacol, 54, 164, 10.1016/j.yrtph.2009.03.012 Igawa, 2011, Engineering the variable region of therapeutic IgG antibodies, MAbs, 3, 243, 10.4161/mabs.3.3.15234